New opportunities to treat the T315I-Bcr-Abl mutant in chronic myeloid leukaemia: Tyrosine kinase inhibitors and molecules that act by alternative mechanisms

Current Medicinal Chemistry

Volumn 17, Issue 13, 2010, Pages 1220-1245

  Schenone, S ^a   Brullo, C ^a   Botta, M ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Bcr Abl; Chronic myeloid leukaemia; Imatinib; Inhibitors; Mutation; Resistance; T315I; Tyrosine kinase

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 [2 METHOXY 5 (2,4,6 TRIMETHOXYSTYRYLSULFONYLMETHYL)ANILINO]PROPIONIC ACID; 2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; AP 23846; AURORA KINASE INHIBITOR; BAG 956; BCR ABL PROTEIN; BENZOTRIAZOLE DERIVATIVE; BORTEZOMIB; CDDO ME; CT 32228; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DANUSERTIB; DCC 2036; DEFOROLIMUS; DORAMAPIMOD; ENZYME INHIBITOR; EVEROLIMUS; FINGOLIMOD; HEAT SHOCK PROTEIN 90 INHIBITOR; KW 2449; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NEVAXAR; NPB 001 05; PANOBINOSTAT; PHA 680626; PP 2A; PPY A; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN T31BI BCR ABL; PROTEIN TYROSINE KINASE INHIBITOR; PYRROLOPYRIDINE INHIBITOR; ROMIDEPSIN; RTA 402; SGX 393; SGX 70430; SORAFENIB; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; UO 126; VE 465; VORINOSTAT; WP 1130; XL 228;

AMINO ACID SUBSTITUTION; APOPTOSIS; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN; CELL TRANSFORMATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; GENE AMPLIFICATION; GENE MUTATION; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77950669895     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710790936310     Document Type: Review

References (199)

1. Soverini, S.; Iacobucci, I.; Baccarani, M.; Martinelli, G. Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. Haematologica, 2007, 92, 437-439.
2. Goldman, J.M. How I treat chronic myeloid leukemia in the Imatinib era. Blood, 2007, 110, 2828-2837.
3. Martinelli, G.; Soverini, S.; Rosti, G.; Cilloni, D. New tyrosine kinase inhibitors in chronic myeloid leukemia. Haematologica, 2005, 90, 534-541. (Pubitemid 40592897)
4. Maekawa, T.; Ashihara, E.; Kimura, S. The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int. J. Clin. Oncol. 2007, 12, 327-340. (Pubitemid 47573416)
5. Kantarjian, H.M.; Talpaz, M.; Giles, F.; O'Brien, S.; Cortes, J. New insight into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann. Intern. Med., 2006, 145, 913-923. (Pubitemid 351639967)
6. Walz, C.; Sattler, M. Novel targeted therapies to overcome Imatinib mesylate resistance in chronic myeloid leukemia. Crit. Rev. Oncol. Hemat., 2006, 57, 145-164. (Pubitemid 43140744)
7. Weisberg, E.; Manley, P.W.; Cowan-Jacob, S.W.; Griffin, J.D. Second generation inhibitors of Bcr-Abl for the treatment of Imatinib-resistant chronic myeloid leukemia. Nat. Rev. Cancer, 2007, 7, 345-356. (Pubitemid 46652483)
8. Kujawski, L.; Talpaz, M. Strategies for overcoming Imatinib resistance in chronic myeloid leukemia. Leukemia Lymphoma, 2007, 48, 2310-2322. (Pubitemid 350253462)
9. Melo, J.V.; Chuah, C. Resistance to Imatinib mesylate in chronic myeloid leukemia. Cancer Lett., 2007, 249, 121-132. (Pubitemid 46452920)
10. Mughal, T.J.; Goldman, J.M. Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia. Clin. Lymphoma Myelom., 2007, 7, suppl 2, S81-S84. (Pubitemid 46848472)
11. Deininger, M.; Buchdunger, E.; Druker, B.J. The development of Imatinib as a therapeutic agent for chronic myeloid leukemia. Blood, 2005, 105, 2640-2653. (Pubitemid 40446252)
12. Vajpai, N.; Strauss, A.; Fendrich, G.; Cowan-Jacob, S.W.; Manley, P.W.; Grzesiek, S.; Jahnke, W. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib J. Biol. Chem., 2008, 283, 18292-18302.
13. Gorre, M.E.; Mohammed, M.; Ellwood, K.; Hsu, N.; Paquette, R.; Pao, P.N.; Sawyers, C.L. Clinical resistence to STI 571 cancer therapy caused by BCR-ABL gene mutation and amplification. Science, 2001, 293, 876-880.
14. O'Hare, T.; Eide, C.A.; Deininger, M.W. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. Exp. Opin. Inv. Drug, 2008, 6, 865-878. (Pubitemid 351864324)
15. Noble, M.E.; Endicott, J.A.; Johnson, N.L. Protein kinase inhibitors: insight into drug design from structure. Science, 2004, 303, 1800-1805. (Pubitemid 38374863)
16. Shah, N.P.; Skaggs, B.J.; Branford, S.; Hughes, T.P.; Nicoll, J.M.; Paquette, R.L.; Sawyers, C.L. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J. Clin. Invest., 2007, 117, 2562-2569.
17. Hochhaus, A.; Kreil, S.; Corbin, A.S.; La Rosee, P.; Muller, M.C.; Lahaye, T.; Hanfstein, B.; Schoch, C.; Cross, N.C.; Berger, U.; Gschaidmeier, H.; Druker, B.J.; Hehlmann, R. Molecular and chromosomal mechanisms of resistance to Imatinib therapy. Leukemia, 2002, 16, 2190-2196.
18. Lee, T.S.; Potts, S.J.; Kantarjian, H.; Cortes, J.; Giles, F.; Albitar, M. Molecular basis explanation for imatinib resistance of Bcr-Abl due to T315I and p-loop mutations from molecular dynamics simulations. Cancer, 2008, 112, 1744-1753. (Pubitemid 351536834)
19. Von Bubnoff, N.; Manley, P.W.; Mestan, J.; Sanger, J.; Peschel, C.; Duyster, J. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood, 2006, 108, 1328-1333. (Pubitemid 44232032)
20. Quintás-Cardama, A. Experimental non-ATP-competitive therapies for chronic myeloid leukemia. Leukemia, 2008, 22, 932-940. (Pubitemid 351689874)
21. Quintás-Cardama, A.; Kantarjian, H.; Cortes, J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat. Rev. Drug Discov., 2007, 6, 834-848. (Pubitemid 47500507)
22. Kantarjian, H.M; Giles, F.; Quintás-Cardama, A.; Cortes, J. Important therapeutic targets in chronic myelogenous leukemia. Clin. Cancer Res., 2007, 13, 1089-1097. (Pubitemid 46424047)
23. Apperley, J.F. Part II: management of resistance to imatinib in chronic myeloid leukemia. Lancet Oncol., 2007, 8, 1116-1128. (Pubitemid 350182968)
24. Jorgensen, H.G.; Holyoake, T.I. Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem. Soc. Trans., 2007, 35, 1347-1351. (Pubitemid 350206497)
25. Ramirez, P.; DiPersio, J.F. Therapy options in Imatinib failures. Oncologist, 2008, 13, 424-434.
26. Padmanabhan, S.; Ravella, S.; Curiel, T.; Giles, F. Current status of therapy for chronic myeloid leukemia: a review of drug development. Fut. Oncol., 2008, 4, 359-377. (Pubitemid 351984088)
27. Noronha, G.; Cao, J.; Chow, C.P.; Dneprovskaia, E.; Fine, R.M.; Hood, J.; Kang, X.; Klebansky, B.; Lohse, D.; Mak, C.C.; McPherson, A.; Palanki, M.S.; Pathak, V.P.; Renick, J.; Soll, R.; Zeng, B. Inhibitors of ABL and the ABL-T315I mutation. Curr. Top Med. Chem., 2008, 8, 905-921.
28. Quintás-Cardama, A.; Cortes, J. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin. Cancer Res., 2008, 14, 4392-4399.
29. Arnold, W.D.; Bounaud, P.; Goseberg, A.; Mcdonald, I.; Steensma, R.W.; Wilson, M.E. WO2006015123.
30. Zhou, T.; Parillon, L.; Li, F.; Wang, Y.; Keats, J.; Lamore, S.; Xu, Q.; Shakespeare, W.; Dalgarno, D.; Zhu, X. Crystal structure of the T315I mutant of Abl kinase. Chem. Biol. Drug Des., 2007, 70, 171-181. (Pubitemid 47305404)
31. Gorre, M.E.; Mohammed, M.; Ellwood, K.; Hsu, N.; Paquette, R.; Rao, P.N.; Sawyers, C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 2001, 293, 876-880.
32. Wallace, A.C.; Laskowski, R.A.; Thornton, J.M. LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions. Prot. Eng., 1995, 8, 127-134.
33. Burley, S.K. Application of FAST™ Fragment-Based Lead Discovery and Structure-Guided Design to Discovery of Small Molecule Inhibitors of BCR-ABL Tyrosine Kinase Active Against the T315I Imatinib-Resistant Mutant. Blood (ASH Annual Meeting Abstracts), 2005, 106, 698.
34. O'Hare, T.; Eide, C.A.; Tyner, J.W.; Corbin, A.S.; Wong, M.J.; Buchanan, S.; Holme, K.; Jessen, K.A.; Tang, C.; Lewis, H.A.; Romero, R.D.; Burley, S.K.; Deininger, M.W. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc. Natl. Acad. Sci. U.S.A., 2008, 105, 5507-5512.
35. Azam, M.; Nardi, V.; Shakespeare, W.C.; Metcalf III, C.A.; Bohacek, R.S.; Wang, Y.; Sundaramoorthi, R.; Sliz, P.; Veach, D.R.; Bornmann, W.C.; Clarkson, B.; Dalgarno, D.C.; Sawyer, T.K.; Daley, G.Q. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 9244-9249.
36. Cao, J.; Fine, R.; Gritzen, C.; Hood, J.; Kang, X.; Klebansky, B.; Lohse, D.; Mak, C.C.; McPherson, A.; Noronha, G.; Palanki, M.S.; Pathak, V.P.; Renick, J.; Soll, R.; Zeng, B.; Zhu, H. The design and preliminary structure activity relationship studies of benzotriazines as potent inhibitors of Abl and Abl-T315I enzymes. Bioorg. Med. Chem. Lett., 2007, 17, 5812-5818.
37. Gumireddy, K.; Baker, S.J.; Cosenza, S.C.; John, P.; Kang, A.D.; Robell, K.A.; Reddy, M.V.R.; Reddy, E.P. A non-ATP-competitive inhibitor of BCR-ABL overrides Imatinib resistance. Proc. Natl. Acad. Sci. U.S.A., 2005, 102, 1992-1997.
38. Donato, N.J.; Wu, J.Y.; Stapley, J.; Lin, H.; Arlinghaus, R.; Aggarwal, B.B.; Shishodia, S.; Albitar, M.; Hayes, K.; Kantarjian, H.; Talpaz, M. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res., 2004, 64, 672-677. (Pubitemid 38120909)
39. Van Etten, R.A.; Chan, W.W.; Zaleskas, V.M.; Evangelista, P.; Lazarides, K.; Peng, C.; Li, S.; Wise, S.C.; Petillo, P.; Flynn, D.L. DCC-2036: A novel switch pocket inhibitor of ABL tyrosine kinase with therapeutic efficacy against BCR-ABL T315I in vitro and in a CML mouse model. Blood (ASH Annual Meeting Abstracts), 2007, 110, 463.
40. Carmena, M.; Earnshaw, W.C. The cellular geography of aurora kinases Nat. Rev. Mol. Biol., 2003, 4, 842-854.
41. Carpinelli, P.; Moll, J. Aurora kinases and their inhibitors: more than one target and one drug. Adv. Exp. Med. Biol., 2008, 10, 54-73.
42. Harrington, E.A.; Bebbington, D.; Moore, J.; Rasmussen, R.K.; Ajose-Adeogun, A.O.; Nakayama, T.; Graham, J.A.; Demur, C.; Hercend, T.; Diu-Hercend, A.; Su, M.; Golec, J.M.C.; Miller, K.M. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med., 2004, 10, 262-267.
43. Cheethman, G.M.; Charlton, P.A.; Golec, J.M.; Pollard, J.R. Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett., 2007, 251, 323-329.
44. Carter, T.A.; Wodicka, L.M.; Shah, N.P.; Velasco, A.M.; Fabian, M.A.; Treiber, D.K.; Milanov, Z.V.; Atteridge, C.E.; Biggs III, W.H.; Edeen, P.T.; Floyd, M.; Ford, J.M.; Grotzfeld, R.M.; Herrgard, S.; Insko, D.E.; Mehta, S.A.; Patel, H.K.; Pao,W.; Sawyers, C.L.; Varmus, H.; Zarrinkar, P.P.; Lockhart, D.J. Inhibition of drug-resistant mutants of ABL, KIT and EGF receptor kinases. Proc. Natl. Acad. Sci. U.S.A., 2005, 102, 11011-11016.
45. Giles, F.J.; Cortes, J.; Jones, D.; Bergstrom, D.; Kantarjian, H.; Freedman, S.J. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood, 2007, 109, 500-502.
46. Samanta, A.K.; Lin, H.; Sun, T.; Kantarjian, H.; Arlinghaus, R.B. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res., 2006, 66, 6468-6472. (Pubitemid 44085597)
47. Martinelli, G.; Soverini, S.; Iacobucci, I.; Baccarani, M. MK-0457: a light at the end of the tunnel? Blood, 2007, 109, 396-397. (Pubitemid 46105931)
48. Young, M.A.; Shah, N.P.; Chao, L.H.; Seeliger, M.; Milanov, Z.V.; Biggs III, W.H.; Treiber, D.K.; Patel, H.K.; Zarrinkar, P.P.; Lockhart, D.J.; Sawyers, C.L.; Kuriyan, J. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res., 2006, 66, 1007-1014. (Pubitemid 43168337)
49. Shah, N.P.; Skaggs, B.J.; Branford, S.; Hughes, T.P.; Nicoll, J.M.; Paquette, R.L.; Sawyers, C.L. Sequential ABL kinase inhibitor therapy selects for compound drug resistant BCR-ABL mutations with altered oncogenic potency. J. Clin. Invest., 2007, 117, 2562-2569.
50. Dai, Y.; Chen, S.; Venditti, C.A.; Pei, X.Y.; Nguyen, T.K.; Dent, P.; Grant, S. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to Imatinib mesylate. Blood, 2008, 112, 793-804.
51. Akahane, D.; Tauchi, T.; Okabe, S.; Nunoda, K.; Ohyashiki, K. Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies. Cancer Sci., 2008, 99, 1251-1257. (Pubitemid 351676639)
52. Fancelli, D.; Moll, J.; Varasi, M.; Bravo, R.; Artico, R.; Berta, D.; Bindi, S.; Cameron, A.; Candiani, I.; Cappella, P.; Carpinelli, P.; Croci, W.; Forte, B.; Giorgini, M.L.; Klapwijk, J.; Marsiglio, A.; Pesenti, E.; Rocchetti, M.; Riletto, F.; Severino, D.; Soncini, C.; Storici, P.; Tonani, R.; Zugnoni, P.; Vinello, P. 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J. Med. Chem., 2006, 49, 7247-7251.
53. Modugno, M.; Casale, E.; Soncini, C.; Rosettani, P.; Colombo, R.; Lupi, R.; Rusconi, L.; Fancelli, D.; Carpinelli, P.; Cameron, A.D.; Isacchi, A.; Moll, J. Crystal structure of the T315I Abl mutant in complex with the aurora kinase inhibitor PHA-739358. Cancer Res., 2007, 67, 7987-7990. (Pubitemid 47395130)
54. Gontarewicz, A.; Balabanov, S.; Keller, G.; Colombo, R.; Graziano, A.; Pesenti, E.; Benten D.; Bokemeyer, C.; Fiedler, W.; Moll, J.; Brümmendorf, T.H. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood, 2008, 111, 4355-4364.
55. Paquette, R.L.; Shah, N.P.; Sawyers, C.L.; Martinelli, G.; John, N.; Chalukya, M.; Rocchetti, M.; Fiocchi, C.; Comis, S.; Capolongo, L.; Laffranchi, B. PHA-739358, an Aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL. Blood (ASH Annual Meeting Abstracts), 2007, 110, 1030.
56. Gontarewicz, A.; Balabanov, S.; Keller, G.; Panse, J.; Schafhausen, P.; Bokemeyer, C.; Fiedler, W.; Moll, J.; Brümmendorf, T.H. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases. Leuk. Res., 2008, 32, 1857-1865.
57. Fancelli, D.; Isacchi, A.; Modugno, M.; Moll, J.; Rusconi, L.; Soncini, C.; Lupi, R. WO 2007113212, 2007.
58. Fancelli, D.; Isacchi, A.; Modugno, M.; Moll, J.; Rusconi, L.; Soncini, C.; Lupi, R. WO 2007113198, 2007.
59. Zhang, W. 171 POSTER Inhibition of the drug-resistant T315l mutant of BCR-Abl, Eur. J. Cancer Suppl., 2006, 4, 54.
60. Shah, N.P.; Kasap, C.; Paquette, R.; Cortes, J.; Pinilla, J.; Talpaz, M.; Bui, L.A.; Clary, D.O. Targeting drug-resistant CML and Ph+- ALL with the spectrum selective protein kinase inhibitor XL228. Blood (ASH Annual Meeting Abstracts), 2007, 110, 474.
61. Shiotsu, Y.; Kiyoi, H.; Ozeki, K.; Umehara, H.; Shimizu, M.; Akinaga, S.; Naoe T. KW-2449, a novel multi-kinase inhibitor against FLT3, Abl, FGFR1 and Aurora, suppresses the growth of AML both in vitro and in vivo. Blood (ASH Annual Meeting Abstracts), 2007, 110, 1832.
62. Cortes, J.; Roboz, G.J.; Kantarjian, H.; Feldman, E.; Karp, J.; Pollack, A.; Sandy, K.; Rao, N.; Akinaga, S.; Levis, M. A phase I dose escalation study of KW-2449, an oral multi-kinase inhibitor against FLT3, Abl, FGFR1 and Aurora in patients with relapsed/refractory AML, treatment resistant/intolerant CML, ALL and MDS. Blood (ASH Annual Meeting Abstracts), 2007, 110, 909.
63. Howard, S.; Berdini, V.; Boulstridge, J.A.; Carr, M.G.; Cross, D.M.; Curry, J.; Devine, L.A.; Early, T.R.; Fazal, L.; Gill, A.L.; Heathcote, M.; Maman, S.; Matthews, J.E.; McMenamin, R.L.; Navarro, E.F.; O'Brien, M.A.; O'Reilly, M.; Rees, D.C.; Reule, M.; Tisi, D.; Williams, G.; Vinković, M.; Wyatt, P.G. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J. Med. Chem., 2009, 52, 379-388.
64. Ravandi, F.; Foran, J.; Verstovsek, S.; Cortes, J.; Wierda, W.; Boone, P.; Borthakur, G.; Sweeney, T.; Kantarjian, H. A phase I trial of AT9283, a multitargeted kinase inhibitor, in patients with refractory hematological malignancies. Blood (ASH Annual Meeting Abstracts), 2007, 110, 904.
65. Regan, J.; Breitfelder, S.; Cirillo, P.; Gilmore, T.; Graham, A.G.; Hickey, E.; Klaus, B.; Madwed, J.; Moriak, M.; Moss, N.; Pargellis, C.; Pav, S.; Proto, A.; Swinamer, A.; Tong, L.; Torcellini, C. Pyrazole urea based inhibitors of p38 MAPK: from lead compound to clinical candidate. J. Med. Chem., 2002, 45, 2994-3008. (Pubitemid 34721521)
66. Dumas, J.; Smith, R.A.; Lowinger, T.B. Recent developments in the discovery of protein kinase inhibitors from the urea class. Curr. Opin. Drug Discov. Devel., 2004, 7, 600-616.
67. Schenone, S.; Brullo, C.; Botta, M. Small molecules ATP-competitive inhibitors of FLT3: A chemical overview. Curr. Med. Chem. 2008, 15, 3113-3132.
68. Schenone, S.; Bondavalli, F.; Botta, M. Antiangiogenic agents: an update on small molecule VEGFR inhibitors. Curr. Med. Chem. 2007, 14, 2495-2516. (Pubitemid 47618038)
69. Cuenda, A.; Rousseau, S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim. Biophys. Acta. 2007, 1773, 1358-1375.
70. Malemud, C.J. Inhibitors of stress-activated protein/mitogen-activated protein kinase pathways. Curr. Opin. Pharmacol., 2007, 7, 339-343. (Pubitemid 46731194)
71. Fabian, M.A.; Biggs, W.H.; Treiber, D.K.; Atteridge, C.E.; Azimioara, M.D.; Benedetti, M.G.; Carter, T.A.; Ciceri, P.; Edeen, P.T.; Floyd, M.; Ford, J.M.; Galvin, M.; Gerlach, J.L.; Grotzfeld, R.M.; Herrgard, S.; Insko, D.E.; Insko, M.A.; Lai, A.G.; Lélias, J.M.; Mehta, S.A.; Milanov, Z.V.; Velasco, A.M.; Wodicka, L.M.; Patel, H.K.; Zarrinkar, P.P.; Lockhart, D.J. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotecnol., 2005, 23, 329-336. (Pubitemid 41094421)
72. O'Hare, T.; Druker, B.J. BIRB-796 is not an effective ABL(T315I) inhibitor. Nat. Biotechnol., 2005, 10, 1209-1210.
73. Steelman, L.S.; Pohnert, S.C.; Shelton, J.G.; Franklin, R.A.; Bertrand, F.E.; McCubrey, J.A. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia, 2004, 18, 189-218.
74. Steelman, L.S.; Abrams, S.L.; Whelan, J.; Bertrand, F.E.; Ludwig, D.E.; Bäsecke, J.; Libra, M.; Stivala, F.; Milella, M.; Tafuri, A.; Lunghi, P.; Bonati, A.; Martelli, A.M.; McCubrey, J.A. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia, 2008, 22, 686-707. (Pubitemid 351565618)
75. McCubrey, J.A.; Steelman, L.S.; Abrams, S.L.; Bertrand, F.E.; Ludwig, D.E.; Bäsecke, J.; Libra, M.; Stivala, F.; Milella, M.; Tafuri, A.; Lunghi, P.; Bonati, A.; Martelli, A.M. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia, 2008, 22, 708-722. (Pubitemid 351565619)
76. Zebedin, E.; Freissmuth, M.; Sexl, V. Signal interception-based therapies - a double-edged sword in Bcr/abl-induced malignancies? Leuk. Lymphoma, 2008, 49, 620-624. (Pubitemid 351517199)
77. Chang, F.; Steelman, L.S.; Shelton, J.G.; Lee, J.T.; Navolanic, P.M.; Blalock, W.L.; Franklin, R.; McCubrey, J.A. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway. Int. J. Oncol., 2003, 22, 469-480.
78. Alvarado, Y.; Giles, F.J. Ras as a therapeutic target in hematologic malignancies. Expert Opin. Emerg. Drugs, 2007, 12, 271-284.
79. Harousseau, J.L. Farnesyltransferase inhibitors in hematologic malignancies. Blood Rev., 2007, 21, 173-182.
80. Karp, J.E.; Lancet, J.E. Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies. Cancer Invest., 2007, 25, 484-494.
81. Martinelli, G.; Iacobucci, I.; Paolini, S.; Ottaviani, E. Farnesyl-transferase inhibition in hematologic malignancies: the clinical experience with tipifarnib. Clin. Adv. Hematol. Oncol., 2008, 6, 303-310.
82. Jabbour, E.; Kantarjian, H.; Cortes, J. Clinical activity of tipifarnib in hematologic malignancies. Expert Opin. Investig. Drugs, 2007, 16, 381-392. (Pubitemid 46394861)
83. Cortes, J.; Quintás-Cardama, A.; Garcia-Manero, G.; O'Brien, S.; Jones, D.; Faderl, S.; Ebarb, T.; Giles, F.; Thomas, D.; Kantarjian, H. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer, 2007, 110, 2000-2006. (Pubitemid 350036859)
84. Jabbour, E.; Kantarjian, H.; Talpaz, M.; Jones, D.; O'Brien, S.; Giles, F.; Garcia-Manero, G.; Ravandi, F.; Faderl, S.;Verstovsek, S.; Rios, M.B.; Cortes, J. Outcome of salvage therapy in patients (pts) with Chronic Myeloid Leukemia (CML) who failed imatinib after developing BCR-ABL kinase mutation. Blood (ASH Annual Meeting Abstracts), 2005, 106, 1092.
85. Hoover, R.R.; Mahon, F.X.; Melo, J.V.; Daley, G.Q. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood, 2002, 100, 1068-1071.
86. Borthakur, G.; Kantarjian, H.; Daley, G.; Talpaz, M.; O'Brien, S.; Garcia-Manero, G.; Giles, F.; Faderl, S.; Sugrue, M.; Cortes, J. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer, 2006, 106, 346-352. (Pubitemid 43100443)
87. Jørgensen, H.G.; Holyoake, T.L. Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem. Soc. Trans., 2007, 35, 1347-1351. (Pubitemid 350206497)
88. Copland, M.; Pellicano, F.; Richmond, L.; Allan, E.K.; Hamilton, A.; Lee, F.Y.; Weinmann, R.; Holyoake, T.L. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood, 2008, 111, 2843-2853.
89. Huntly, B.J.; Gilliland, D.G. Cancer biology: summing up cancer stem cells. Nature, 2005, 435, 1169-1170. (Pubitemid 40943069)
90. Wang, D.; Boerner, S.A.; Winkler, J.D.; LoRusso, P.M. Clinical experience of MEK inhibitors in cancer therapy. Biochim. Biophys. Acta, 2007, 1773, 1248-1255. (Pubitemid 47161034)
91. Yu, C.; Krystal, G.; Varticovksi, L.; McKinstry, R.; Rahmani, M.; Dent, P.; Grant, S. Pharmacologic mitogen-activated protein/ extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res., 2002, 62, 188-199. (Pubitemid 34074004)
92. Nguyen, T.K.; Rahmani, M.; Harada, H.; Dent, P.; Grant, S. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood, 2007, 109, 4006-4015. (Pubitemid 46641754)
93. Dong, S.; Kang, S.; Lonial, S.; Khoury, H.J.; Viallet, J.; Chen, J. Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070. Leukemia, 2008, 22, 572-577. (Pubitemid 351386727)
94. Nguyen, T.K.; Rahmani, M.; Gao, N.; Kramer, L.; Corbin, A.S.; Druker, B.J.; Dent, P.; Grant, S. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate. Clin. Cancer Res., 2006, 12, 2239-2247.
95. Bustelo, X.R.; Sauzeau, V.; Berenjeno, I.M. GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. Bioessays, 2007, 29, 356-370.
96. Williams, D.A.; Zheng, Y.; Cancelas, J.A. Rho GTPases and regulation of hematopoietic stem cell localization. Methods Enzymol., 2008, 439, 365-393.
97. Thomas, E.K.; Cancelas, J.A.; Zheng, Y.; Williams, D.A. Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis. Leukemia, 2008, 22, 898-904.
98. Gao, Y.; Dickerson, J.B.; Guo, F.; Zheng, J.; Zheng, Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc. Natl. Acad. Sci. U.S.A., 2004, 101, 7618-7623. (Pubitemid 38658078)
99. Thomas, E.K.; Cancelas, J.A.; Chae, H.D.; Cox, A.D.; Keller, P.J.; Perrotti, D.; Neviani, P.; Druker, B.J.; Setchell, K.D.; Zheng, Y.; Harris, C.E.; Williams, D.A. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABLinduced myeloproliferative disease. Cancer Cell, 2007, 12, 467-478.
100. Kim, J.H.; Chu, S.C.; Gramlich, J.L.; Pride, Y.B.; Babendreier, E.; Chauhan, D.; Salgia, R.; Podar, K.; Griffin, J.D.; Sattler, M. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood, 2005, 105, 1717-1723. (Pubitemid 40223695)
101. Kharas, M.G.; Janes, M.R.; Scarfone, V.M.; Lilly, M.B.; Knight, Z.A.; Shokat, K.M.; Fruman, D.A. Ablation of PI3K blocks BCRABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J. Clin. Invest., 2008, 118, 3038-3050.
102. Rioux-Bilan, A.; Daubon, T.; Morel, F.; Kitzis, A.; Bourmeyster, N. Inhibition of PI3K synergistically enhances the apoptotic effect of STI-571 on p210(bcr-abl)-transformed cells in a Rac1-dependent manner. Leuk. Res., 2008, 32, 517-519. (Pubitemid 351295925)
103. Zebedin, E.; Simma, O.; Schuster, C.; Putz, E.M.; Fajmann, S.; Warsch, W.; Eckelhart, E.; Stoiber, D.; Weisz, E.; Schmid, J.A.; Pickl, W.F.; Baumgartner, C.; Valent, P.; Piekorz, R.P.; Freissmuth, M.; Sexl, V. Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance. Blood, 2008, 112, 4655-4664.
104. Stauffer, F.; Maira, S.M.; Furet, P.; García-Echeverría, C. Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway. Bioorg. Med. Chem. Lett., 2008, 18, 1027-1030.
105. Weisberg, E.; Banerji, L.; Wright, R.D.; Barrett, R.; Ray, A.; Moreno, D.; Catley, L.; Jiang, J.; Hall-Meyers, E.; Sauveur-Michel, M.; Stone, R.; Galinsky, I.; Fox, E.; Kung, A.L.; Griffin, J.D. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood, 2008, 111, 3723-3734.
106. Zhu, J.; Huang, J.W.; Tseng, P.H.; Yang, Y.T.; Fowble, J.; Shiau, C.W.; Shaw, Y.J.; Kulp, S.K.; Chen, C.S. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositidedependent protein kinase-1 inhibitors. Cancer Res., 2004, 64, 4309-4318.
107. Tseng, P.H.; Lin, H.P.; Zhu, J.; Chen, K.F.; Hade, E.M.; Young, D.C.; Byrd, J.C.; Grever, M.; Johnson, K.; Druker, B.J.; Chen, C.S. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. Blood, 2005, 105, 4021-4027.
108. Easton, J.B.; Houghton, P.J. mTOR and cancer therapy. Oncogene, 2006, 25, 6436-6446.
109. Huang, S.; Bjornsti, M.A.; Houghton, P.J. Rapamycins: mechanism of action and cellular resistance. Cancer Biol. Ther., 2003, 2, 222-232.
110. Sillaber, C.; Mayerhofer, M.; Böhm, A.; Vales, A.; Gruze, A.; Aichberger, K.J.; Esterbauer, H.; Pfeilstöcker, M.; Sperr, W.R.; Pickl, W.F.; Haas, O.A.; Valent, P. Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur. J. Clin. Invest., 2008, 38, 43-52. (Pubitemid 350293855)
111. Del Bufalo, D.; Ciuffreda, L.; Trisciuoglio, D.; Desideri, M.; Cognetti, F.; Zupi, G.; Milella, M. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res., 2006, 66, 5549-5554. (Pubitemid 43927103)
112. Shor, B.; Zhang, W.G.; Toral-Barza, L.; Lucas, J.; Abraham, R.T.; Gibbons, J.J.; Yu, K. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res., 2008, 68, 2934-2943. (Pubitemid 351556294)
113. Yee, K.W; Zeng, Z.; Konopleva, M.; Verstovsek, S.; Ravandi, F.; Ferrajoli, A.; Thomas, D.; Wierda, W.; Apostolidou, E.; Albitar, M.; O'Brien, S.; Andreeff, M.; Giles, F.J. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res., 2006, 12, 5165-5173.
114. Rizzieri, D.A.; Feldman, E.; Dipersio, J.F.; Gabrail, N.; Stock, W.; Strair, R.; Rivera, V.M.; Albitar, M.; Bedrosian, C.L.; Giles, F.J. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res., 2008, 14, 2756-2762.
115. Van Etten, RA. Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk. Res., 2004, 28 Suppl 1, S21-S28.
116. Coppo, P. ; Flamant, S.; De Mas, V.; Jarrier, P.; Guillier, M.; Bonnet, M.L.; Lacout, C.; Guilhot, F.; Vainchenker, W.; Turhan, A.G. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br. J. Haematol., 2006, 134, 171-179.
117. Verstovsek, S.; Manshouri, T.; Quintás-Cardama, A.; Harris, D.; Cortes, J.; Giles, F.J.; Kantarjian, H.; Priebe, W.; Estrov, Z. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin. Cancer Res., 2008, 14, 788-796. (Pubitemid 351231161)
118. Bartholomeusz, G.; Talpaz, M.; Bornmann, W.; Kong, L.Y.; Donato, N.J. Degrasyn activates proteasomal-dependent degradation of c-Myc. Cancer Res., 2007, 67, 3912-3918.
119. Bartholomeusz, G.A.; Talpaz, M.; Kapuria, V.; Kong, L.Y., Wang, S.; Estrov, Z.; Priebe, W.; Wu, J.; Donato, N.J. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood, 2007, 109, 3470-3478.
120. Rahmani, M.; Davis, E.M.; Bauer, C.; Dent, P.; Grant, S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J. Biol. Chem., 2005, 280, 35217-35227. (Pubitemid 41532709)
121. Rahmani, M.; Nguyen, T.K.; Dent, P.; Grant, S. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Mol. Pharmacol., 2007, 72, 788-795. (Pubitemid 47351213)
122. Huang, M.; Dorsey, J.F.; Epling-Burnette, P.K.; Nimmanapalli, R.; Landowski, T.H.; Mora, L.B.; Niu, G.; Sinibaldi, D.; Bai, F.; Kraker, A.; Yu, H.; Moscinski, L.; Wei, S.; Djeu, J.; Dalton, W.S.; Bhalla, K.; Loughran, T.P.; Wu, J.; Jove. R. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene, 2002, 21, 8804-8816. (Pubitemid 36132401)
123. Dasmahapatra, G.; Yerram, N.; Dai, Y.; Dent, P.; Grant, S. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 downregulation. Clin. Cancer Res., 2007, 13, 4280-4290. (Pubitemid 47108172)
124. Calderwood, S.K.; Khaleque, M.A.; Sawyer, D.B.; Ciocca, D.R. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem. Sci., 2006, 31, 164-172. (Pubitemid 43361923)
125. Gorre, M.E.; Ellwood-Yen, K.; Chiosis, G.; Rosen, N.; Sawyers, C.L. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood, 2002, 100, 3041-3044.
126. Nimmanapalli, R.; O'Bryan, E.; Bhalla, K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Ablpositive human leukemic blasts. Cancer Res., 2001, 61, 1799-1804.
127. Radujkovic, A.; Schad, M.; Topaly, J.; Veldwijk, M.R.; Laufs, S.; Schultheis, B.S.; Jauch, A.; Melo, J.V.; Fruehauf, S.; Zeller, W.J. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL - Inhibition of P-glycoprotein function by 17-AAG. Leukemia, 2005, 19, 1198-1206.
128. George, P.; Bali, P.; Annavarapu, S.; Scuto, A.; Fiskus, W.; Guo, F.; Sigua, C.; Sondarva, G.; Moscinski, L.; Atadja, P.; Bhalla, K. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood, 2005, 105, 1768-1774. (Pubitemid 40223701)
129. Hollingshead, M.; Alley, M.; Burger, A.M.; Borgel, S.; Pacula-Cox, C.; Fiebig, H.H.; Sausville, E.A. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother. Pharmacol., 2005, 56, 115-125.
130. Nguyen, T.K.; Rahmani, M.; Gao, N.; Kramer, L.; Corbin, A.S.; Druker, B.J.; Dent, P.; Grant, S. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate. Clin. Cancer Res., 2006, 12, 2239-2247.
131. Ge, J.; Normant, E.; Porter, J.R.; Ali, J.A.; Dembski, M.S.; Gao, Y.; Georges, A.T.; Grenier, L.; Pak, R.H.; Patterson, J.; Sydor, J.R.; Tibbitts, T.T.; Tong, J.K.; Adams, J.; Palombella, V.J. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17- amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J. Med. Chem., 2006, 49, 4606-4615. (Pubitemid 44162687)
132. Sydor, J.R.; Normant, E.; Pien, C.S.; Porter, J.R.; Ge, J.; Grenier, L.; Pak, R.H.; Ali, J.A.; Dembski, M.S.; Hudak, J.; Patterson, J.; Penders, C.; Pink, M.; Read, M.A.; Sang, J.; Woodward, C.; Zhang, Y.; Grayzel, D.S.; Wright, J.; Barrett, J.A.; Palombella, V.J.; Adams, J.; Tong, J.K. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc. Natl. Acad. Sci. USA, 2006, 103, 17408-17413.
133. Peng, C.; Brain, J.; Hu, Y.; Goodrich, A.; Kong, L.; Grayzel, D.; Pak, R.; Read, M.; Li, S. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood, 2007, 110, 678-685. (Pubitemid 47105407)
134. Peng, C.; Li, D.; Li, S. Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors. Cell Cycle, 2007, 6, 2227-2231. (Pubitemid 47547697)
135. Pocaly, M.; Lagarde, V.; Etienne, G.; Ribeil, J.A.; Claverol, S.; Bonneu, M.; Moreau-Gaudry, F.; Guyonnet-Duperat, V.; Hermine, O.; Melo, J.V.; Dupouy, M.; Turcq, B.; Mahon, F.X.; Pasquet, J.M. Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia. Leukemia, 2007, 21, 93-101. (Pubitemid 44921840)
136. Pocaly, M.; Lagarde, V.; Etienne, G.; Dupouy, M.; Lapaillerie, D.; Claverol, S.; Vilain, S.; Bonneu, M.; Turcq, B.; Mahon, F.X.; Pasquet, J.M. Proteomic analysis of an imatinib-resistant K562 cell line highlights opposing roles of heat shock cognate 70 and heat shock 70 proteins in resistance. Proteomics, 2008, 8, 2394-2406.
137. Guo, F.; Rocha, K.; Bali, P.; Pranpat, M.; Fiskus, W.; Boyapalle, S.; Kumaraswamy, S.; Balasis, M.; Greedy, B.; Armitage, E.S.; Lawrence, N.; Bhalla, K. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res., 2005, 65, 10536-10544. (Pubitemid 41743748)
138. Puissant, A.; Grosso, S.; Jacquel, A.; Belhacene, N.; Colosetti, P.; Cassuto, J.P.; Auberger, P. Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol. FASEB J., 2008, 22, 1894-1904. (Pubitemid 351811466)
139. Chakraborty, P.K.; Mustafi, S.B.; Ganguly, S.; Chatterjee, M.; Raha, S. Resveratrol induces apoptosis in K562 (chronic myelogenous leukemia) cells by targeting a key survival protein, heat shock protein 70. Cancer Sci., 2008, 99, 1109-1116. (Pubitemid 351676621)
140. Carew, J.S.; Giles, F.J.; Nawrocki, S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett., 2008, 269, 7-17.
141. Bali, P.; Pranpat, M.; Bradner, J.; Balasis, M.; Fiskus, W.; Guo, F.; Rocha, K.; Kumaraswamy, S.; Boyapalle, S.; Atadja, P.; Seto, E.; Bhalla, K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem., 2005, 280, 26729-26734. (Pubitemid 41040705)
142. de Bono, J.S.; Kristeleit, R.; Tolcher, A.; Fong, P.; Pacey, S.; Karavasilis, V.; Mita, M.; Shaw, H.; Workman, P.; Kaye, S.; Rowinsky, E.K.; Aherne, W.; Atadja, P.; Scott, J.W.; Patnaik, A. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein- 90 inhibitory profile, in patients with advanced solid tumors. Clin. Cancer Res., 2008, 14, 6663-6673.
143. Nimmanapalli, R.; Fuino, L.; Bali, P.; Gasparetto, M.; Glozak, M.; Tao, J.; Moscinski, L.; Smith, C.; Wu, J.; Jove, R.; Atadja, P.; Bhalla, K. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res., 2003, 63, 5126-5135. (Pubitemid 37022654)
144. Weisberg, E.; Catley, L.; Kujawa, J.; Atadja, P.; Remiszewski, S.; Fuerst, P.; Cavazza, C.; Anderson, K.; Griffin, J.D. Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. Leukemia, 2004, 18, 1951-1963.
145. George, P.; Bali, P.; Annavarapu, S.; Scuto, A.; Fiskus, W.; Guo, F.; Sigua, C.; Sondarva, G.; Moscinski, L.; Atadja, P.; Bhalla, K. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood, 2005, 105, 1768-1776. (Pubitemid 40223701)
146. Rao, R.; Fiskus, W.;Yang, Y.; Lee, P.; Joshi, R.; Fernandez, P.; Mandawat, A.; Atadja, P.; Bradner, J.E.; Bhalla, K. HDAC6 inhibition enhances 17-AAG - mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood, 2008, 112, 1886-1893.
147. Fiskus, W.; Pranpat, M.; Bali, P.; Balasis, M.; Kumaraswamy, S.; Boyapalle, S.; Rocha, K.; Wu, J.; Giles, F.; Manley, P.W.; Atadja, P.; Bhalla, K. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr- Abl-expressing human leukemia cells. Blood, 2006, 108, 645-652. (Pubitemid 44061366)
148. Fiskus, W.; Wang, Y.; Joshi, R.; Rao, R.; Yang, Y; Chen, J.; Kolhe, R.; Balusu, R.; Eaton, K.; Lee, P.; Ustun, C.; Jillella, A.; Buser, C.A.; Peiper, S.; Bhalla, K. Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin. Cancer Res., 2008, 14, 6106-6115.
149. Carew, J.S.; Giles, F.J.; Nawrocki, S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett., 2008, 269, 7-17.
150. Carew, J.S.; Nawrocki, S.T.; Kahue C.N.; Zhang, H.; Yang, C.; Chung, L.; Houghton, J.A.; Huang, P.; Giles, F.J.; Cleveland, J.L. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood, 2007, 110, 313-322.
151. Okabe, S.; Tauchi, T.; Nakajima, A.; Sashida, G.; Gotoh, A.; Broxmeyer, H.E.; Ohyashiki, J.H.; Ohyashiki, K. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis. Stem Cells Dev., 2007, 16, 503-514.
152. Neviani, P.; Santhanam, R.; Trotta, R.; Notari, M.; Blaser, B.W.; Liu, S.; Mao, H.; Chang, J.S.; Galietta, A.; Uttam, A.; Roy, D.C.; Valtieri, M.; Bruner-Klisovic, R.; Caligiuri, M.A.; Bloomfield, C.D.; Marcucci, G.; Perrotti, D. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell, 2005, 8, 355-368. (Pubitemid 41579831)
153. Perrotti, D.; Neviani, P. ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. Br. J. Cancer, 2006, 95, 775-781. (Pubitemid 44500626)
154. Neviani, P.; Santhanam, R.; Oaks, J.J.; Eiring, A.M.; Notari, M.; Blaser, B.W.; Liu, S.; Trotta, R.; Muthusamy, N.; Gambacorti-Passerini, C.; Druker, B.J.; Cortes, J.; Marcucci, G.; Chen, C.S.; Verrills, N.M.; Roy, D.C.; Caligiuri, M.A.; Bloomfield, C.D.; Byrd, J.C.; Perrotti, D. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J. Clin. Invest., 2007, 117, 2408-2421. (Pubitemid 47494343)
155. Perrotti, D.; Neviani, P. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias Cancer Metastasis Rev., 2008, 27, 159-168.
156. Reed, J.C.; Pellecchia, M. Apoptosis-based therapies for hematologic malignancies. Blood, 2005, 106, 408-418.
157. Kitada, S.; Reed, J.C. MCL-1 promoter insertions dial-up aggressiveness of chronic leukemia. J. Natl. Cancer Inst., 2004, 96, 642-643.
158. Krajewska, M.; Kitada, S.; Winter, J.N.; Variakojis, D.; Lichtenstein, A.; Zhai, D.; Cuddy, M.; Huang, X.; Luciano, F.; Baker, C.H.; Kim, H.; Shin, E.; Kennedy, S.; Olson, A.H.; Badzio, A.; Jassem, J.; Meinhold-Heerlein, I.; Duffy, M.J.; Schimmer, A.D.; Tsao, M.; Brown, E.; Sawyers, A.; Andreeff, M.; Mercola, D.; Krajewski, S.; Reed, J.C. Bcl-B expression in human epithelial and nonepithelial malignancies. Clin. Cancer Res., 2008, 14, 3011-3021.
159. Oltersdorf, T.; Elmore, S.W.; Shoemaker, A.R.; Armstrong, R.C.; Augeri, D.J.; Belli, B.A.; Bruncko, M.; Deckwerth, T.L.; Dinges, J.; Hajduk, P.J.; Joseph, M.K.; Kitada, S.; Korsmeyer, S.J.; Kunzer, A.R.; Letai, A.; Li, C.; Mitten, M.J.; Nettesheim, D.G.; Ng, S.; Nimmer, P.M.; O'Connor, J.M.; Oleksijew, A.; Petros, A.M.; Reed, J.C.; Shen, W.; Tahir, S.K.; Thompson, C.B.; Tomaselli, K.J.; Wang, B.; Wendt, M.D.; Zhang, H.; Fesik, S.W.; Rosenberg, S.H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 2005, 435, 677-681.
160. Kuroda, J.; Kimura, S.; Andreeff, M.; Ashihara, E.; Kamitsuji, Y.; Yokota, A.; Kawata, E.; Takeuchi, M.; Tanaka, R.; Murotani, Y.; Matsumoto, Y.; Tanaka, H.; Strasser, A.; Taniwaki, M.; Maekawa, T. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br. J. Haematol., 2008, 140, 181-190. (Pubitemid 350265045)
161. Karin, M.; Cao, Y.; Greten, F.R.; Li, Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer, 2002, 2, 301-310. (Pubitemid 37328783)
162. Lee, D.F.; Hung, M.C. Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin. Cancer Res., 2008, 14, 5656-5662.
163. Ziegelbauer, K.; Gantner, F.; Lukacs, N.W.; Berlin, A.; Fuchikami, K.; Niki, T.; Sakai, K.; Inbe, H.; Takeshita, K.; Ishimori, M.; Komura, H.; Murata, T.; Lowinger, T.; Bacon, K.B. A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad antiinflammatory activity. Br. J. Pharmacol., 2005, 145, 178-192.
164. Duncan, E.A.; Goetz, C.A.; Stein, S.J.; Mayo, K.J.; Skaggs, B.J.; Ziegelbauer, K.; Sawyers, C.L.; Baldwin, A.S. IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells. Mol. Cancer Ther., 2008, 7, 391-397.
165. Ahmad, R.; Raina, D.; Meyer, C.; Kharbanda, S.; Kufe, D. Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. J. Biol. Chem., 2006, 281, 35764-35769. (Pubitemid 46041307)
166. Samudio, I.; Konopleva, M.; Pellicano, H.; Huang, P.; Frolova, O.; Bornmann, W.; Ying, Y.; Evans, R.; Contractor, R.; Andreeff, M. A novel mechanism of action of methyl-2-cyano-3,12 dioxoolean-1,9 diene-28-oate: direct permeabilization of the inner mitochondrial membrane to inhibit electron transport and induce apoptosis. Mol. Pharmacol., 2006, 69, 1182-1193.
167. Samudio, I.; Kurinna, S.; Ruvolo, P.; Korchin, B.; Kantarjian, H.; Beran, M.; Dunner, K. Jr.; Kondo, S.; Andreeff, M.; Konopleva, M. Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells. Mol. Cancer Ther. 2008, 7, 1130-1139.
168. Fennell, D.A.; Chacko, A.; Mutti, L. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene, 2008, 27, 1189-1197. (Pubitemid 351294694)
169. Boccadoro, M. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. Nat. Clin. Pract. Oncol., 2006, 3, 374-387.
170. Gatto, S.; Scappini, B.; Pham, L.; Onida, F.; Milella, M.; Ball, G.; Ricci, C.; Divoky, V.; Verstovsek, S.; Kantarjian, H.M.; Keating, M.J.; Cortes-Franco, J.E.; Beran M. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica, 2003, 88, 853-863. (Pubitemid 37128085)
171. Yong, A.S.; Keyvanfar, K.; Hensel, N.; Eniafe, R.; Savani, B.N.; Berg, M.; Lundqvist, A.; Adams, S.; Sloand, E.M.; Goldman, J.M.; Childs, R.; Barrett, A.J. Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood, 2009, 113, 875-882.
172. Dasmahapatra, G.; Nguyen, T.K.; Dent, P.; Grant S. Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl. Leuk. Res., 2006, 30, 1263-1272. (Pubitemid 44223728)
173. Hitt, E. Homoharringtonine effective in CML patients. Lancet Oncol., 2002, 3, 259.
174. de Lavallade, H.; Khorashad, J.S.; Davis, H.P.; Milojkovic, D.; Kaeda, J.S.; Goldman, J.M.; Apperley, J.F.; Marin, D. Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood, 2007, 110, 2779-2780. (Pubitemid 47523217)
175. Legros, L.; Hayette, S.; Nicolini, F.E.; Raynaud, S.; Chabane, K.; Magaud, J.P.; Cassuto, J.P.; Michallet, M. BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge? Leukemia, 2007, 21, 2204-2206.
176. Quintás-Cardama, A.; Cortes, J. Homoharringtonine for the treatment of chronic myelogenous leukemia. Expert Opin. Pharmacother., 2008, 9, 1029-1037. (Pubitemid 351593746)
177. Quintás-Cardama, A.; Cortes, J. Omacetaxine mepesuccinate-a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies. IDrugs, 2008, 11, 356-372. (Pubitemid 351677896)
178. Kaur, G.; Narayanan, V.L.; Risbood, P.A.; Hollingshead, M.G.; Stinson, S.F.; Varma, R.K.; Sausville, E.A. Synthesis, structure-activity relationship, and p210(bcr-abl) protein tyrosine kinase activity of novel AG 957 analogs. Bioorg. Med. Chem., 2005, 13, 1749-1761.
179. Svingen, P.A.; Tefferi, A.; Kottke, T.J.; Kaur, G.; Narayanan, V.L.; Sausville, E.A.; Kaufmann, S.H. Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin. Cancer Res., 2000, 6, 237-249.
180. Orsolic, N.; Golemovic, M.; Quintás-Cardama, A.; Scappini, B.; Manshouri, T.; Chandra, J.; Basic, I.; Giles, F.; Kantarjian, H.; Verstovsek, S. Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. Cancer Sci., 2006, 97, 952-960. (Pubitemid 44151279)
181. Chandra, J.; Tracy, J.; Loegering, D.; Flatten, K.; Verstovsek, S.; Beran, M.; Gorre, M.; Estrov, Z.; Donato, N.; Talpaz, M.; Sawyers, C.; Bhalla, K.; Karp, J.; Sausville, E.; Kaufmann, S.H. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood, 2006, 107, 2501-2506.
182. La Rosée, P.; Jia, T.; Demehri, S.; Härtel, N.; de Vries, P. ; Bonham, L.; Hollenback, D.; Singer, J.W.; Melo, J.V.; Druker, B.J.; Deininger, M.W. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib. Clin. Cancer Res., 2006, 12, 6540-6546.
183. Wu, X.J.; Hua, X. Targeting ROS: selective killing of cancer cells by a cruciferous vegetable derived pro-oxidant compound. Cancer Biol Ther., 2007, 6, 646-647.
184. Zhang, H.; Trachootham, D.; Lu, W.; Carew, J.; Giles, F.J.; Keating, M.J.; Arlinghaus, R.B.; Huang, P. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia, 2008, 22, 1191-1199. (Pubitemid 351833787)
185. http://www.piramallifesciences.com/
186. Yassin, M.; Wasser, S.P.; Mahajna, J. Substances from the medicinal mushroom Daedalea gibbosa inhibit kinase activity of native and T315I mutated Bcr-Abl. Int. J. Oncol., 2008, 32, 1197-1204.
187. Ren, P.; Wang, X.; Gray, N.S.; Liu, Y.; Sim, T. WO 2006002367, 2006.
188. Ren, P., Wu, B.; Zhang, G.; Xie, Y.; Okram, B.; Nikulin, V.; Wang, X.; Choi, H.S. WO 2007134259, 2007.
189. Housey, G.M. WO 2007037898, 2007.
190. Berdini, V.; Curry, J.E.; Gallagher, N.J.; Gill, A.L.; Lyons, J.F. WO 2007077435, 2007.
191. Smith, R.; Nagarathnam, D. WO 2008079968, 2008.
192. Joshi, K.S.; Sivakumar, M.; Aware, V.S.; Wagh, V.S.; Deshpande, A.; Sarde, A.G.; Sharma, S. WO 2008026125, 2008.
193. Kimura, S. Second generation Abl kinase inhibitors and novel compounds to eliminate the Bcr-Abl/T315I clone. Recent Pat. Anti-Canc., 2006, 1, 347-355.
194. Chen, C.; Eastman, B.; Gosberg, A.; Gradl, S.N.; Hirst, G.; Hopkins, S.; Nguyen, K.T.; Pracitto, R.; Sprengeler, P.A.; Steensma, R.W. WO 2008124848, 2008.
195. http://clinicaltrials.gov/ct2/show/NCT00827138
196. http://clinicaltrials.gov/ct2/show/NCT00335868
197. http://clinicaltrials.gov/ct2/show/NCT00522990
198. http://clinicaltrials.gov/ct2/show/NCT0085007
199. http://clinicaltrials.gov/ct2/show/NCT00375219